New data released today at the annual meeting of the American Psychiatric Association show that the NeuroStar TMS Therapy System(R) induced statistically and clinically meaningful response and remission in patients with Major Depressive Disorder (MDD) during the acute phase of therapy, which were maintained through one year of treatment. At the end of acute treatment, 62 percent of patients achieved symptomatic improvement while 41 percent reported complete remission. At 12 months, 68 percent of patients achieved symptomatic improvement while 45 percent reported complete remission. Maintenance of benefit was observed under a pragmatic regimen of continuation antidepressant medication and access to TMS reintroduction for symptom recurrence.
For many people, the treatment of depression involves prescription drugs. But what happens if the pills don’t do the trick? Read more at wptv.com
The London Psychiatry Centre has adapted a technology known as Transcranial Magnetic Stimulation, which focuses magnetic beams into the brain, to treat depression. Read more at www.telegraph.co.uk
A new transcranial magnetic stimulation (TMS) society open to all TMS providers has been established. The Clinical TMS Society (Clinical TMS) coordinates TMS practices and connects physician and non-physician members from across the world. Read more at www.psychiatrictimes.com